The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
As a first-line treatment for patients with marginal zone lymphoma, the combination of bendamustine with rituximab (BR) conferred no advantage in overall survival over rituximab monotherapy, which can yield durable remissions with less toxicity, according to a study published in the journal Haematologica.
The Phase 1 trial evaluates DuoCAR20.19.22-D95 in adults with relapsed or refractory B-cell malignancies who have often failed prior CAR T-cell treatments.
Researchers conducted a systematic review of phase III trials to assess the correlation between these two endpoints in MCL studies. The final analysis included 16 trials assessing 19 treatment options in nearly 6,000 adult patients.
This issue of SOHO Insider features an article on US patient representation in global trials, an interview with Dr. Naval Daver, and photos from SOHO
In this session from the SOHO Insider Community Oncology Brown Bag series, Luke Fletcher, MD, presents on an exploration of barriers and solutions for activating
The discussion also covers the study’s safety profile and the potential for these early-stage immunotherapies to achieve long-term curative results.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
